Literature DB >> 22575317

Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.

Davide Castagno1, Hicham Skali, Madoka Takeuchi, Karl Swedberg, Salim Yusuf, Christopher B Granger, Eric L Michelson, Marc A Pfeffer, John J V McMurray, Scott D Solomon.   

Abstract

OBJECTIVES: The aim of this study was to explore the relationship between baseline resting heart rate and outcomes in patients with chronic heart failure (HF) according to baseline left ventricular ejection fraction (LVEF) and cardiac rhythm.
BACKGROUND: Elevated resting heart rate is associated with worse outcomes in patients with HF and reduced LVEF. Whether this association is also found in patients with HF and preserved LVEF is uncertain, as is the predictive value of heart rate in patients in atrial fibrillation (AF).
METHODS: Patients enrolled in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program were divided into groups by tertiles of baseline heart rate. Cox proportional hazard models were used to investigate the association between heart rate and pre-specified outcomes in the overall population as well as in subgroups defined according to LVEF (≤ 40% vs. >40%) and presence (or absence) of AF at baseline.
RESULTS: After adjusting for predictors of poor prognosis, patients in the highest heart rate tertile had worse outcomes when compared with those in the lowest heart rate group (e.g., for the composite of cardiovascular death or HF hospital stay hazard ratio: 1.23, 95% confidence interval: 1.11 to 1.36, p < 0.001). The relationship between heart rate and outcomes was similar across LVEF categories and was not influenced by beta-blocker use (p value for interaction >0.10 for both endpoints). However, amongst patients in AF at baseline, heart rate had no predictive value (p value for interaction <0.001).
CONCLUSIONS: Resting heart rate is an important predictor of outcome in patients with stable chronic HF without AF, regardless of LVEF or beta-blocker use.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575317     DOI: 10.1016/j.jacc.2011.12.044

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  47 in total

1.  Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.

Authors:  Marco R Di Tullio; Min Qian; John L P Thompson; Arthur J Labovitz; Douglas L Mann; Ralph L Sacco; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; Susan Graham; Gregory Y H Lip; Bruce Levin; J P Mohr; Richard Buchsbaum; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Shunichi Homma
Journal:  Stroke       Date:  2016-06-28       Impact factor: 7.914

2.  Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study.

Authors:  Ali Vazir; Brian Claggett; Susan Cheng; Hicham Skali; Amil Shah; David Agulair; Christie Mitchell Ballantyne; Orly Vardeny; Scott D Solomon
Journal:  JAMA Cardiol       Date:  2018-03-01       Impact factor: 14.676

3.  Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction.

Authors:  Ali Valika; Kim Paprockas; Dana Villines; Maria Rosa Costanzo
Journal:  Clin Cardiol       Date:  2018-05-14       Impact factor: 2.882

Review 4.  The effects of heart rate control in chronic heart failure with reduced ejection fraction.

Authors:  Dario Grande; Massimo Iacoviello; Nadia Aspromonte
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 5.  Novel drugs for heart rate control in heart failure.

Authors:  Agata Bielecka-Dabrowa; Stephan von Haehling; Jacek Rysz; Maciej Banach
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

6.  Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction.

Authors:  Wesley T O'Neal; Pratik B Sandesara; Ayman Samman-Tahhan; Heval M Kelli; Muhammad Hammadah; Elsayed Z Soliman
Journal:  Eur J Prev Cardiol       Date:  2017-05-09       Impact factor: 7.804

Review 7.  Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure.

Authors:  Jasneet Devgun; Yash B Jobanputra; Michael Arustamyan; Robert Chait; Waqas Ghumman
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

8.  Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.

Authors:  Bart A Mulder; Kevin Damman; Dirk J Van Veldhuisen; Isabelle C Van Gelder; Michiel Rienstra
Journal:  Clin Cardiol       Date:  2017-05-17       Impact factor: 2.882

9.  Cellular FLICE-like inhibitory protein protects against cardiac hypertrophy by blocking ASK1/p38 signaling in mice.

Authors:  Ying Huang; Lianpin Wu; Jian Wu; Yumei Li; Lili Hou
Journal:  Mol Cell Biochem       Date:  2014-08-03       Impact factor: 3.396

10.  Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy.

Authors:  Wilson Nadruz; Erin West; Morten Sengeløv; Gabriela L Grove; Mário Santos; John D Groarke; Daniel E Forman; Brian Claggett; Hicham Skali; Anju Nohria; Amil M Shah
Journal:  Heart       Date:  2018-05-15       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.